Adaptimmune Therapeutics Plc Overview
Latest ROE for Adaptimmune Therapeutics Plc: 239.23% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow239.23%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, ADAP shows a ROE of 239.23%. That is above the Healthcare sector average of 11.15%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 11.15%. Adaptimmune Therapeutics Plc is at 239.23%, which is higher that average. That is roughly 2044.8% above the sector mean. Use the comparison chart on this page to see how ADAP stacks up against individual peers as well.
Check the historical chart to see whether ADAP's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Adaptimmune Therapeutics Plc with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Adaptimmune Therapeutics Plc's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 239.23%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 11.15%, while ADAP is at 239.23%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
